CBD Headlines
Home » NewsRoom Articles » Page 204
ThursdayAug 11, 2016 10:04 am

Laguna Blends, Inc. (LAGBF) Looking to Expand Pro Athlete Brand Strategy for Pro369

Before the opening bell, Laguna Blends, Inc. (CSE: LAG) (OTC: LAGBF) (FRANKFURT: LB6A.F) offered investors an update on the success of its pro athlete branding strategy for Pro369, the company’s hemp protein-based functional beverage product. In addition to announcing the renewal of Emmanual Arceneaux, a player in the Canadian Football League, as a brand ambassador for a second year, Laguna announced that it is currently in ongoing negotiations with a number of other professional athletes across North America who enjoy the health benefits offered by Laguna’s products. In June, Laguna reported its results from the first 11 weeks of sales…

Continue Reading

TuesdayAug 09, 2016 9:35 am

Laguna Blends, Inc. (LAGBF) Acquires Exclusive Distribution Rights for Swiss-Made CBD Skin Care Products

Before the opening bell, Laguna Blends, Inc. (CSE : LAG) (OTC : LAGBF) (FRANKFURT : LB6A.F) announced its entry into an agreement with ISO International, LLC through which it has acquired the exclusive right to market, promote and distribute seven cannabidiol (CBD) skin care products produced by Cannaceuticals of California, USA (“Canna”). Under the terms of the agreement, Laguna will be required to pay a one-time licensing fee of $100,000 and place a minimum purchase order of $1.5 million during the first two years of the initial term. “We are excited to announce the closing of this transaction, which firmly…

Continue Reading

MondayAug 08, 2016 2:12 pm

Laguna Blends, Inc. (LAGBF) Adds Bryan Loree as CFO, Corporate Secretary and Director

Earlier today, Laguna Blends, Inc. (CSE: LAG) (LB6A.F) (OTC: LAGBF) announced the appointment of Bryan Loree to the positions of chief financial officer and corporate secretary. He will also join the company’s board of directors, effective immediately. Loree has roughly a decade of experience providing chief financial officer, accounting, financing and management services to a number of issuers on both the TSX Venture Exchange and the Canadian Securities Exchange, as well as a selection of private businesses. Loree will replace Stuart Gray, Laguna’s founder and chief executive officer, who formerly served as the company’s acting chief financial officer. “It’s a…

Continue Reading

MondayJul 18, 2016 3:43 pm

Laguna Blends, Inc. (CSE: LAG) (LB6A.F) (OTC: LAGBF) Highlights Recent Milestones Related to Growth Strategy

Before the opening bell, Laguna Blends, Inc. (OTC: LAGBF) issued a news release recapping some of its recent milestones related to its planned entry into the $121 billion global skin care industry. The most recently announced milestone related to this goal was the company’s entry into a non-binding letter of intent to acquire the exclusive license brand name and existing inventory of CannaCeuticals of California, USA (“Canna”), which was originally announced in a news release issued on July 7. Under the terms of this agreement, Laguna will receive an exclusive license to sell Canna’s cannabidiol (CBD) skin care products in…

Continue Reading

WednesdayJul 06, 2016 5:19 pm

Laguna Blends, Inc. (CSE: LAG) (LB6A.F) (OTC: LAGBF) Enters Letter of Intent to Acquire Exclusive Distribution Rights for Cannabidiol Skin Care Line

Before the opening bell, Laguna Blends, Inc. (OTC: LAGBF) announced the execution of a non-binding letter of intent with Cannaceuticals of California, USA (Canna) through which it plans to enter into a definitive manufacturing and exclusive license agreement for Canna’s cannabidiol (CBD) skin care line. The two parties have agreed to an exclusivity period running through July 29, during which additional negotiations and signing of the manufacturing and license agreement are expected to take place. “Canna has spent a tremendous amount of time and financial resources to create what we believe is the highest quality CBD skin care line available…

Continue Reading

TuesdayJul 05, 2016 5:23 pm

Cesca Therapeutics, Inc. (KOOL) Advancing the Practice of Cell Therapy for Regenerative Medicine

Cesca Therapeutics, Inc. (NASDAQ: KOOL) describes itself as being “engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine.” The company focuses on three markets: therapies, medical and diagnostic devices, and cell manufacturing and banking services. Most recently, the company’s CLIRST III trial was approved by the U.S Food and Drug Administration (FDA). The CLIRST III trial is being undertaken to determine the safety and efficacy of Cesca’s SurgWerks-CLI platform. This platform is for the treatment of people with late-stage, no option or critical limb ischemia (CLI). The CLIRST III clinical study “is a prospective,…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722

CBDWire

303 S Broadway, Suite 317-CBDW
Denver, CO 80209
(303) 498-7722

Copyright © . CBDWire / 303 S Broadway, Suite 317-CBDW, Denver, CO 80209 (303) 498-7722 / Disclaimers